What is the optimal duration for vigabatrin monotherapy in patients with infantile spasms: 6 months or longer?

Area of Science:

• Pediatric Neurology
• Clinical Pharmacology

Background:

• Infantile Spasms (IS) treatment with Vigabatrin (VGB) requires careful duration management due to potential neurotoxicity and retinal risks.
• The optimal treatment duration for VGB in IS patients remains undetermined.

Purpose of the Study:

• To assess the risk of spasm relapse after a 6-month VGB treatment course in IS patients who initially responded well.
• To compare outcomes between patients receiving 6 months versus longer VGB treatment.

Main Methods:

• Retrospective and prospective analysis of 44 infants with IS who achieved spasm and hypsarrhythmia remission after 4 weeks of VGB.
• Patients were categorized into a 6-month VGB group (n=34) and a >6-month VGB group (n=10).
• Outcomes, including spasm relapse and late-onset epilepsy, were compared between groups.

Main Results:

• No patients in either the 6-month or >6-month VGB group experienced a relapse of infantile spasms.
• Late-onset epilepsy (focal seizures) occurred in 5/37 patients within 6-9 months of VGB initiation, with similar incidence across treatment durations.
• In the 6-month group, patients with non-identified etiology (NIE) did not develop other seizure types.

Conclusions:

• A 6-month VGB treatment course appears sufficient for achieving and maintaining remission in IS patients, particularly those with NIE.
• Shortening VGB treatment duration to 6 months may be a viable strategy to mitigate toxicity risks without compromising efficacy.
• Further research could refine optimal VGB treatment durations based on etiology and response.